U.S. Reviewing if Moderna Shot Tied to Higher Heart Inflammation Risk in Young Adults

Publisher's Picks
618

Translate to Spanish or other 102 languages!

Image for illustration only

By Celine Castronuovo – The Hill

- Advertisement -

Federal health officials are conducting an investigation into the effects of the Moderna COVID-19 vaccine following new research that showed it may be linked to a higher risk of heart inflammation in young adults than previously though, according to a report from The Washington Post.

Two people familiar with the review told the Post that the heart condition, called myocarditis, is likely still extremely rare, but added that the Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are looking into new Canadian data suggesting a greater risk among a specific demographic that have received the Moderna vaccine. Read more, click here.

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
Texas says schools now must notify families of positive COVID-19 cases in classrooms
Next article
FDA Approves First COVID-19 Vaccine

More Articles

DHR Health Brownsville Hosts Inspiring Weight Loss Support Group, Nov. 13th

Mega Doctor News Cameron County, Texas - If you are considering weight loss...

DHR Health and RGV College Celebrate Fifth Nursing Apprenticeship Graduating Class

DHR Health and Rio Grande Valley College celebrated the fifth graduating class of their Registered Nurse Apprenticeship Program on September 3, 2026, at the Edinburg Conference Center at Renaissance, marking a milestone for an initiative designed to help working nurses advance their careers

STHS Honors Longtime Employee with Veteran of the Year Award

From serving our nation to caring for patients across the Rio Grande Valley, nearly 100 veterans employed throughout South Texas Health System's (STHS) 12 facilities continue to make a difference through their work in healthcare.

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 
- Advertisement -